D+Q study in both young and aged mice shown to cause neuropathy in the brain including demylelination. Treatment regime (dosing) was apparently the same as used by others in mice that showed increased survival so it wasnt like they were giving massive doses of D+Q.
"To determine whether D+Q treatment had any effects on
myelination in the brain, we treated a cohort of aged (22 mo)
C57Bl6/J mice with senolytics, dasatinib and quercetin (5 mg/
kg and 50 mg/kg, respectively), through oral gavage (Fig. 1A).
This treatment paradigm provides intermittent administration
of D+Q which increased posttreatment survival rates of aged
mice, as developed by others (31, 32). "
https://doi.org/10.1073/pnas.2524897123
Proceedings of the National Academy of Sciences
Vol. 123, No. 12
Mar 2026
Senolytic treatment induces oligodendrocyte dysfunction and demyelination in the corpus callosum
Significance
The pharmacological combination of dasatinib and quercetin (D+Q), widely reported as a means of eliminating senescent cells from aged tissues to treat diseases (a.k.a. “senolytics”), and currently being tested in multiple clinical trials, when administered to healthy mice results in profound white matter injury in the central nervous system. This report provides evidence that this senolytic combination not only causes neuropathology but also provides data which support induction of the unfolded protein response as a plausible mechanism through which these senolytics affect oligodendrocytes. We propose that these data highlight a less understood means of demyelination not mediated by oligodendrocyte death with potential positive implications for understanding disease, while also warranting caution for its widespread use clinically.